



AML3D Limited

Unit 4, 136 Mooringe Avenue
North Plympton SA 5037
AUSTRALIA

info@aml3d.com
+61 8 8258 2658
www.aml3d.com

24 July 2025

JUNE 2025 QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C

AML3D Limited (ASX: AL3) ("AML3D" or "the Company"), a leader in large scale Wire Additive Manufacturing ("WAM") technology and 3D metal printing solutions, is pleased to provide the Quarterly Activities Report and Appendix 4C for the quarter ended 30 June 2025 (Q4FY25).

KEY HIGHLIGHTS DURING THE QUARTER

Continuing strong growth in the US market has **delivered A\$2.9m in customer receipts** for the June 2025 Quarter, a **77% increase** on the prior comparable period (**PCP**). AML3D leveraged the official opening, in June, of the company's Manufacturing and Technology centre in Stow, Ohio¹ to continue to strengthen and deepen relationships with key opinion leaders (**KOL**) and partners in the US Defence, Government and Manufacturing sectors. In July, the US Department of the Navy issued a Letter of Intent (**LOI**) identifying AML3D's proprietary ARCEMY technology as key to meeting the additive manufacturing needs of the US Navy's Maritime Industrial Base (**MIB**), a **potential \$150 - \$200 million opportunity**².

Key highlights during the quarter included:

- Official opening of US manufacturing and technology centre in Stow, Ohio
- US advocacy program positions AML3D as pivotal to meeting MIB additive manufacturing needs.
- US leadership strengthened as the architect of US Navy MIB program, Frederick Stefany joins US Board.
- The largest custom ARCEMY® System to date goes online at Austal USA
- Entry into the UK defence sector with alloy test contract with MoD prime supplier BAE systems
- Strong cash position of \$30.4m to fund US expansion and to establish a European manufacturing base

GROWTH STRATEGY

The official opening of AML3D's US Technology Centre is timely and key to the Company's growth strategy. It positions AML3D to take advantage of the \$150 to \$200 million opportunity outlined in the US Department of the Navy LOI issued to AML3D. The LOI identifies AML3D's ARCEMY technology as 'pivotal' to US Navy's plans to accelerate MIB manufacturing. The Stow facility rapidly scales AML3D's capabilities to meet this significant and growing demand across the US Defence sector but also across civilian infrastructure and manufacturing applications. The appointment of Mr. Frederick J Stefany, the first Program Manager of the US Navy's Maritime Industrial Base ("MIB"), to the AML3D USA Board³ provides the US leadership team with access to invaluable experience, insights and relationships across the US Navy and Department of Defense.

¹AML3D Ltd, [AML3D opens advanced manufacturing facility in Ohio](#), 20 June 2025

²AML3D Ltd, [US Navy Issues AML3D with Letter of Intent and Forecast](#), 7 July 2025

³AML3D Ltd, [Senior US Navy Program Lead Appointed to Board of AML3D USA](#), 27 June 2025



AML3D launched the 'US Scale up' strategy in February 2023, with an order for a large scale ARCEMY® X advanced manufacturing system for Oak Ridge National Laboratory in Tennessee⁴ in support of the US Navy's submarine industrial base. The US Technology Centre was established with two ARCEMY® systems in December 2024⁵ and with an initial A\$2.27 million order to build and supply an ARCEMY® for the Tennessee Valley Authority ('TVA'), the largest public utility in the USA. The TVA contract marks AML3D's entry into the US energy and utilities market.

Cumulatively, to date, AML3D has secured contracts, primarily with the US Navy and Navy prime suppliers, totaling over A\$19 million.

Supporting AUKUS with supply of US Navy Virginia Class submarine components

The advantages of AML3D's ARCEMY technology were clearly demonstrated with the delivery, over a 5-week period of US Navy's Virginia Class submarine tailpiece components⁶ that traditional manufacturing suppliers required 17 months to complete. The Copper-Nickel tail piece components are undergoing testing and will be in service onboard a Virginia-Class submarine.

This tailpieces order demonstrates how ARCEMY components can match, if not exceed, traditional manufacturing quality standards, can massively improve US Navy Maritime Industrial Base supply chain efficiency and help to establish a resilient and responsive manufacturing base to support the AUKUS defence partnership between the US, the UK and Australia.

AML3D's contribution to the US Navy's Virginia class nuclear submarine program was recognised in January 2025 by the U.S. Program Executive Office Attack Submarines, Admiral Jonathan Rucker, following the order to supply tailpiece components.

Speaking in advance of the Submarine League Conference⁷ in November 2024, Admiral Rucker commented *"Through partnerships like the one with AML3D, we are creating resiliency and robustness domestically as well as in critical areas of Naval operation,"*

US Defence relationships and advocacy

Alongside the US Navy's LOI, the investment in Stow is underpinned by the Manufacturing License Agreement⁸ between AML3D and US Navy procurement partner Blue Forge Alliance (BFA'). BFA is tasked with accelerating the US Navy's adoption of advanced manufacturing (AM') technologies. In September 2024, BFA was awarded US\$951 million by the US government in September 2024 to boost US Navy manufacturing, including scaling additive manufacturing capacity and capabilities. In December 2024 AML3D announced plans to invest a further A\$12 million⁹ to more than double capacity and ensure AML3D USA is well positioned to lead the transition to additive manufacturing in the US.

In March and May of 2025, AML3D undertook US advocacy programs^{10,11}, which included site visits that revealed the opportunity to triple the addressable US Navy market by supplying WAM® technology and solutions in support of the wider US Maritime Industrial Base (MIB') that includes surface ships, missiles and submarines.

US Government advocacy

To boost MIB manufacturing the US Government is prioritising accelerating manufacturing over the costs for shipbuilding. Additive Manufacturing (AM) is recognised as a key driver of strategic manufacturing capability. AML3D's

⁴ AML3D Ltd, [AML3D Enters US Defence Industry with ARCEMY Sale](#), 1 February 2023

⁵ AML3D Ltd, [AML3Ds US Technology Centre Open with Plans to Expand](#), 12 December 2024

⁶ AML3D Ltd, [AML3D Supports AUKUS Supply Chain](#), 6 January 2025

⁷ Naval Submarine League, Annual Symposium & Industry Update, 13-14 November

⁸ AML3D Ltd, [MFA Agreement to Expand AML3D's Delivery to US Navy](#), 12 September 2024

⁹ AML3D Ltd, [AML3Ds US Technology Centre Open with Plans to Expand](#), 12 December 2024

¹⁰ AML3D Ltd, [Investor Presentation June 2025](#), 24 June 2025

¹¹ AML3D Ltd, [Investor Presentation - New US defence markets open to AML3D](#), 31 March 2025

AML3D Limited ACN 602 857 983 / Australian Patent 2019251514. AML3D®, WAM®, WAMSoft®, ARCEMY® are all registered trademarks for AML3D®.



WAM® technology is recognised as part of the AM solutions that are integral to the US Government's National Defense Authorization Act (NDAA) for 2025 and into 2026.

The US SHIPS Act¹² has the aim of creating a fleet of 250 US ships within 10 years and the US SPEED Act¹³ promotes the acceleration of US defense procurement processes and both are currently being presented to US law makers. As part of AML3D's 'US Scale up' senior executives have been engaging with key partners and opinion leaders amongst the US Department of Defence, the MIB supply chain and elected US representatives.

Expanded opportunities within the US Army and the Marine Corps

AML3D's US advocacy program revealed broad recognition amongst KOL of the Company's unique capability to support U.S. defence manufacturing and the KOL's are actively promoting and accelerating additive manufacturing programs. The establishment of the MIB, by AML3D USA Board member Mr. Frederick J Stefany in February 2024, has created an immediate tripling of AML3D's addressable US Defence market¹⁴. The MIB includes an early adopter of AML3D's WAM® technology, the US Navy's Submarine Industrial Base (**SIB**). AML3D's success supporting the SIB is expected to translate to opportunities to support surface ships, aircraft carriers and munitions, such as missiles.

AML3D's US advocacy program has also highlighted opportunities for WAM® technology to support vehicle, artillery and missile programs across the US Army and Marine Corps. AML3D is also exploring opportunities to develop a pilot program for containerized, easily portable and easy to deploy at, or close to, the point of need ARCEMY® systems with the US Marine Corps.

Collaboration with Austal as a US Navy Prime supplier

This strong endorsement for AML3D's advanced AM solutions within the MIB is expected to drive demand for ARCEMY® Systems across the US Navy's Prime suppliers. AML3D is targeting near-term sales with existing Navy prime customer, Austal, as well as Huntington Ingalls.

AML3D is also collaborating with Austal on ways to flex ARCEMY® system configurations to allow maximum effectiveness across Austal's existing and new facilities. This collaboration is expected to form the basis for a longer-term partnership with Austal that may include the development of a multi ARCEMY® array of systems to create AM printing at scale to support Naval shipyards.

Embedding ARCEMY within US Defense Manufacturing Training Programs

A key consideration for the rapid adoption of AML3D's WAM® technology within US Shipbuilding is the availability of access to skilled AM workers. AML3D is engaging with both the State of Virginia's Institute for Advanced Learning & Research (IALR) and the US Navy's Accelerated Training in Defense Manufacturing (ATDM) program¹⁵ to accelerate training of AM workers for the US Navy and broader manufacturing industry. Both programs have embraced ARCEMY®, creating an opportunity to secure AML3D as the gold standard for the new AM workforce.

European expansion supports AUKUS partner the UK.

AML3D also has allocated A\$5 million of capital to explore expanding its ACREMY manufacturing footprint into Europe¹⁶. The planned European manufacturing base will launch with an ARCEMY system that will help improve defence supply chains for AUKUS partner, the UK, and provide support to additional, significant European Defence markets.

¹² <https://www.congress.gov/bill/118th-congress/house-bill/10493/text>

¹³ <https://www.congress.gov/bill/118th-congress/house-bill/9265>

¹⁴ AML3D Ltd, [Investor Presentation - New US defence markets open to AML3D](#), 31 March 2025

¹⁵ AML3D Ltd, [Investor Presentation - New US defence markets open to AML3D](#), 31 March 2025

¹⁶ AML3D Ltd, [AML3D to Double US Manufacturing with A\\$30M Capital Raise](#), 22 November 2024

AML3D Limited ACN 602 857 983 / Australian Patent 2019251514. AML3D®, WAM®, WAMSoft®, ARCEMY® are all registered trademarks for AML3D®.



AML3D has a UK defence alloy test contract in place with BAE Systems for the supply of 8.5 tonnes of Nickel Aluminium Bronze ('NAB') wire feedstock¹⁷. The BAE systems contract, which includes the manufacture and delivery of NAB test blocks and a confidential part to UK defence specifications, has a total valued of A\$1.48 million. Alongside the production of NAB test blocks, AML3D is completing a confidential component manufacturing order for a UK defence prime supplier. Entry into the U.K. Defence market is a key part of the next phase of AML3D's growth strategy.

R&D Investment

AML3D continues to invest in Research and Development to retain the competitive advantage of being a leader in advanced Wire Arc Manufacturing. In the June 2025 quarter AML3D invested close to \$0.8 million, including capital additions, on R&D, with a focus on the ADIR project to increase ARCEMY deposition rates to accelerate component production.

The total budget for the ADIR project is A\$2.24 million, with 50% of total funding provided by the SA Government including \$186,000 received in the March quarter and a further claim of \$390,000 in Q1FY26.

FINANCIAL UPDATE

AML3D is announcing cash receipts of A\$2.9 million in the June quarter, contributing to total Financial Year 2025 cash receipts of \$8.7 million up 4% on pcq.

AML3D's June quarter spend of \$448,000 on R&D brings the total R&D investment for Financial Year 2025 to \$1.1 million. Combined with \$0.7 million in capital equipment for the AIRD project, AML3D has committed close to \$2 million in R&D for FY25.

In addition to the capital investment in R&D, a further \$1.0 million to support US manufacturing contributing to property, plant and equipment investment for the Financial Year 2025 to \$2.1 million.

The company's cash position remains extremely strong at A\$30.4 million on 30 June 2025. AML3D retains the balance sheet strength to fund the company's A\$12 million plan to more than double US manufacturing and A\$5 million plan to establish a European manufacturing and technology centre.

OUTLOOK

AML3D's 'US Scale Up' strategy has already delivered a surge in US Navy contracts for the deployment of ARCEMY® systems and associated alloy and component testing and characterisation. As key part of the US Scale up strategy is proactive engagement with key stakeholders and opinion leaders. This ongoing engagement has already translated to a LOI from the US Navy outlining a \$150 - \$200 million opportunity to support the MIB¹⁸.

The passing of the Trump administrations 'Big Beautiful Bill'¹⁹ is expected to expedite US Government funding for the US Navy MIB. This is expected to drive an acceleration in US Defence contract wins in the second half of calendar 2025. AML3D has good line of sight to near term ARCEMY® system sales to US Navy Primes and there is strong medium to long term demand signals from the US Navy, Marine Corps and Army. The establishment of AML3D's US manufacturing facility means AML3D can easily scale up to meet US defence demand and broader demand to support the AUKUS defence pact between the US, Australia and the UK. The company also has additional capacity at its existing Australian facilities, which will be augmented by the establishment of a European technology centre, to meet demand surges.

¹⁷ AML3D Ltd, [AML3D Expands to UK Defence Market with Alloy Test Contract](#), 15 April 2025

¹⁸ AML3D Ltd, [US Navy Issues AML3D with Letter of Intent and Forecast](#), 7 July 2025

¹⁹ <https://www.congress.gov/bills/119/congress/house-bills/1/text>



Outside of defence, AML3D has entered the US energy and utilities markets through the TVA ARCEMY® system sale²⁰, creating additional growth opportunities. The Company has also strengthened its leadership team with the appointment of Frederick Stefany, an architect of the US Navy Marine Industrial Base. AML3D is very confident of reporting significant US contract wins in the near term.

This announcement has been authorised for release by the Board of AML3D.

For further information, please contact:

Sean Ebert

Managing Director
AML3D Limited
T: +61 8 8258 2658
E: investor@aml3d.com

Hamish McEwin

Chief Financial Officer
AML3D Limited
T: +61 8 8258 2658
E: investor@aml3d.com

About AML3D Limited

AML3D Limited, a publicly listed technology company founded in 2014, utilises new technologies to pioneer and lead metal additive manufacturing globally. Disrupting the traditional manufacturing space, AML3D has developed and patented a Wire Additive Manufacturing (WAM®) process that metal 3D prints commercial, large-scale parts for Aerospace, Defence, Maritime, Manufacturing, Mining and Oil & Gas. AML3D provides parts contract manufacturing, from its Technology Centre in Adelaide Australia, and is the OEM of ARCEMY®, an industrial metal 3D printing system that combines IIoT and Industry 4.0 to enable manufacturers to become globally competitive.

²⁰AML3D Ltd, [AML3D wins \\$2.27M Arcemy X Contract in US Utilities Sector](#), 09 December 2024

AML3D Limited ACN 602 857 983 / Australian Patent 2019251514. AML3D®, WAM®, WAMSoft®, ARCEMY® are all registered trademarks for AML3D®.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AML3D Limited

ABN

55 602 857 983

Quarter ended ("current quarter")

30 June 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	2,908	8,672
1.2 Payments for		
(a) research and development	(448)	(1,069)
(b) product manufacturing and operating costs	(829)	(2,057)
(c) advertising and marketing	(74)	(252)
(d) leased assets	-	-
(e) staff costs	(1,534)	(5,913)
(f) administration and corporate costs	(789)	(2,935)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	139	260
1.5 Interest and other costs of finance paid	(42)	(168)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	207	573
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(462)	(2,889)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(383)	(2,113)
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	5
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(383)	(2,108)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	30,100
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(2,066)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(43)	(378)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(43)	27,656

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	31,358	7,790
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(462)	(2,889)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(383)	(2,108)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(43)	27,656
4.5	Effect of movement in exchange rates on cash held	(72)	(51)
4.6	Cash and cash equivalents at end of period	30,398	30,398

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	10,398	11,358
5.2	Call deposits	20,000	20,000
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	30,398	31,358

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	-
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
N/A		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(462)
8.2 Cash and cash equivalents at quarter end (item 4.6)	30,398
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	30,398
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	66
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 24 July 2025

Authorised by: the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.